Imidazopyrazine Syk Inhibitors for Autoimmune Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis and asthma, often have limitations in effectively targeting Syk activity, which is crucial for B-cell activation and mast cell degranulation, leading to incomplete disease control and potential side effects.
Innovation Solution
Development of chemical entities, specifically imidazopyrazine compounds and their pharmaceutically acceptable salts, that inhibit Syk enzymatic activity, thereby reducing B-cell activation and mast cell degranulation, offering a targeted approach for treating autoimmune, inflammatory, and allergic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then disease control is achieved to some extent, but Syk activity is not effectively inhibited leading to incomplete disease control and potential side effects
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that specifically target and inhibit Syk kinase activity. These compounds act as mediators between the therapeutic goal (inhibiting B-cell and mast cell activation) and the desired outcome (reduced disease activity), providing more precise control compared to existing treatments while reducing off-target side effects
Solution Approach 2:
The patent modifies the therapeutic approach by changing the molecular target parameter from general immune suppression to specific Syk kinase inhibition. By altering the biochemical parameter of Syk enzymatic activity, the treatment achieves better disease control with improved safety profile
2Reliability
If Syk activity is inhibited to improve disease control, then B-cell activation and mast cell degranulation are reduced, but the mechanism requires highly specific compounds to avoid affecting other kinases
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that target only Syk kinase. The chemical structures are optimized with particular substituents and functional groups that interact specifically with Syk's active site, ensuring localized inhibition without affecting other kinases
Solution Approach 2:
The patent segments the kinase family by creating compounds that distinguish Syk from other kinases through specific binding interactions. The molecular design focuses on unique features of Syk's structure, allowing selective inhibition while leaving other kinases unaffected
Data Source
AI summary
Provided are imidazopyrazine compounds, particularly including 6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine, structure below, and methods and formulations for their use in inhibiting Spleen Tyrosine Kinase in treating conditions including B-cell lymphomas or leukemias and inflammatory conditions: